Nancy Reau, MD

The panel of experts offers expert insights and concluding thoughts on the management of primary biliary cholangitis (PBC), emphasizing the importance of personalized treatment strategies, monitoring, and the evolving role of new therapies in improving patient outcomes.

The panel of experts addresses potential challenges in the adoption of peroxisome proliferator-activated receptor (PPAR) agonists for primary biliary cholangitis (PBC), including barriers to access, patient selection, and long-term treatment considerations.

The panel of experts discuss how to determine the effectiveness of treatment in primary biliary cholangitis (PBC), focusing on key clinical markers, biochemical responses, and patient outcomes.

The panel of experts explore the potential integration of peroxisome proliferator-activated receptor (PPAR) agonists into the current treatment landscape for primary biliary cholangitis (PBC) and provides recommendations for patients currently taking fibrates for managing the disease.

The panel of experts examine the long-term data for the recently FDA-approved PPAR-δ agonist elafibranor in the treatment of primary biliary cholangitis (PBC), comparing its clinical findings with those of seladelpar, and explores how to choose the right peroxisome proliferator-activated receptor (PPAR) agonist and assess treatment effectiveness.

The panel of experts discuss the role of effectively treating pruritus, a common and debilitating symptom in over 80% of patients with cholestatic liver diseases like primary biliary cholangitis (PBC), and its importance in the long-term management of the disease.

The panel of experts review the long-term data on the recently FDA-approved PPAR-δ agonist seladelpar for primary biliary cholangitis (PBC), focusing on its efficacy, safety, and impact on liver biochemistry markers over time.

The panel of experts explore the use of FDA-approved peroxisome proliferator-activated receptor (PPAR) agonists in the management of primary biliary cholangitis (PBC), discussing their scientific basis, how they differ from fibrates, and their role in combination with ursodeoxycholic acid (UDCA) or as monotherapy for UDCA-intolerant patients.

The panel of experts cover second-line treatment options for primary biliary cholangitis (PBC), focusing on the use of obeticholic acid (OCA), its mechanism of action, management of adverse effects like pruritus and fatigue, the role of off-label fibrates, and strategies for assessing and adjusting therapy based on patient response and adverse effects.

The panel of experts outline the primary treatment goals for patients with primary biliary cholangitis (PBC), detailing how goals adjust based on disease severity, the role of ursodeoxycholic acid (UDCA) as first-line therapy, and the challenges that may require therapy modifications based on biochemical response.

The panel of experts focus on strategies for distinguishing primary biliary cholangitis (PBC) from other liver diseases with similar clinical presentations, emphasizing key diagnostic markers and assessment techniques.

The panel of experts examine major complications and comorbidities associated with primary biliary cholangitis (PBC), including vitamin deficiencies, osteoporosis, and conditions like metabolic-associated steatohepatitis (MASH), autoimmune disorders, and obesity.

The panelists discuss the typical presentation of primary biliary cholangitis (PBC), covering common and uncommon symptoms, the diagnostic journey, and key clinical and laboratory assessments used to identify disease markers.

The panelists explain the pathophysiology of primary biliary cholangitis (PBC), highlighting how immune-mediated processes contribute to progressive liver damage in affected patients.

In this video segment, Reau, Trivedi, and Hirschfield discuss pipeline developments and other advances in primary biliary cholangitis they are most looking forward to.

In this video segment, Reau, Trivedi, and Hirschfield discuss how the emergence of second-generation PPAR agonists like seladelpar and elafibranor impact PBC management.

In this video segment, Reau, Trivedi, and Hirschfield discuss how treatment sequencing in PBC has evolved over time with the emergence of new second-line therapies and considerations for determining sequencing.

In this video segment, Reau, Trivedi, and Hirschfield discuss the EMA opinion on obeticholic acid and its impact on discussions about second-line therapies amid the influx of new treatment options available for patients.

In this video segment, Reau, Trivedi, and Hirschfield discuss the availability of new second-line treatment options and their role in PBC management compared to traditional therapies like UDCA and OCA.

In this video segment, Reau, Trivedi, and Hirschfield discuss recent shifts in treatment goals for patients with PBC and a new focus on timely intervention with second-line options.

Medical experts share insights on managing refractory hepatic encephalopathy and provide concluding remarks and essential points on the condition.

The group of hepatic encephalopathy (HE) professionals acknowledges the challenges and potential overwhelm faced by busy primary care practices when managing patients with HE, and they provide practical clinical pearls and advice to support these clinicians in delivering effective care and improving patient outcomes.

Medical experts discuss the management of patients with hepatic encephalopathy (HE) receiving lactulose and rifaximin therapy and develop diarrhea or a urinary tract infection (UTI) in the outpatient setting.

The expert panel on hepatic encephalopathy (HE) presents clinical recommendations for managing patients with recurrent or episodic HE in the outpatient setting.

The panel reviews the current American Association for the Study of Liver Diseases (AASLD) guideline recommendations for treating patients with hepatic encephalopathy (HE), and they also discuss the role of rifaximin, its ability to be prescribed by primary care clinicians, and its safety profile.

Nancy Reau, MD, leads a discussion on the current abnormality-targeting agents used to prevent and treat hepatic encephalopathy (HE) by addressing the gut-liver axis, specifically focusing on lactulose or lactitol and rifaximin, while also explaining their mechanisms of action and adverse event profiles.

Kimberly Brown, MD, explains the role of the gut microbiota in the development of hepatic encephalopathy (HE) and describes the common alterations to the microbiota that occur because of chronic liver disease.

Arun B. Jesudian, MD, discusses strategies to prevent the progression of cirrhosis, which include targeting microbiome abnormalities to improve the gut-liver axis, enhancing circulatory function, treating the inflammatory state, and addressing portal hypertension.

The panel examines the evolving role of primary care clinicians in managing patients with hepatic encephalopathy (HE) and emphasizes the importance of consulting specialists when necessary, providing insights from the perspective of a primary care clinician.

The expert panelists explore the symptoms and risk factors associated with HE, the challenges in diagnosing the condition due to its resemblance to neuropsychiatric l disorders, and the methods used to assess and grade the severity of the disease.